ReviewLeukemia2016

Rationale, application and clinical qualification for NT-proBNP as a surrogate end point in pivotal clinical trials in patients with AL amyloidosis.

G Merlini et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.